




A.**MPro****B.**


Supplementary Figure 1. Titration of the anti-His antibody binding to individual viral antigen-coated beads. **A. Estimation of the antibody-binding capacity of MPro beads.** Magnetic beads coated with SARS-CoV-2 MPro were incubated with the indicated amounts of anti-his-tag antibody, followed by anti-rabbit-PE and analysed by flow cytometry. The histogram shows the fluorescence intensity for each anti-His concentration. **B. Estimation of the antibody-binding capacity of SARS-CoV-2 antigen-coated beads.** The same was done in parallel with different magnetic beads, each one coated with one SARS-CoV-2 antigen: Spike, the Receptor Binding Domain (RBD) of the S, the nucleocapsid protein (NP) and 3CL main protease (Mpro). Three dilutions of anti-His antibody were used: 16 ng/ml, 80 ng/ml and 400 ng/ml. The plots represent the MFI values obtained for each condition tested.





Multiantigen assay for SARS-CoV-2 antibody detection. Four different SARS-CoV-2 His-tagged antigens (Mpro, NP, S and RBD) were covalently coupled to magnetic beads labeled with dyes showing different fluorescence intensity in the APC and PerCP channels. Equal amounts of the different bead populations were mixed in the same tube and incubated with dilutions of plasma from patients or healthy donors, as indicated. Antibodies bound to the antigen were developed with fluorophore-conjugated anti-human Ig (FITC, PE and PE-Cyanine7) and samples were analysed by flow cytometry. Statistic comparison was carried out using a Mann-Whitney test.

Supplementary Figure 3

A. IgG



B. IgA**C. IgM**

Multiantigen assay for SARS-CoV-2 shows no cross-reactivity with other respiratory diseases. Four different SARS-CoV-2 His-tagged antigens (Mpro, NP, S and RBD) were covalently coupled to magnetic beads labeled with dyes showing different fluorescence intensity in the APC and PerCP channels. Equal amounts of the different bead populations were mixed in the same tube and incubated with dilutions of plasma from patients or healthy donors, as indicated. Antibodies bound to the antigen were developed with fluorophore-conjugated anti-human Ig (FITC, PE and PE-Cyanine7) and samples were analysed by flow cytometry. **A. IgG.** **B. IgA.** **C. IgM**

Supplementary Table 1. Patient demographic and clinical data for severity study

		N=29	%
Gender	Male	25	86
	Female	4	14
Age	40-60	19	66
	61-70	5	17
	> 71	5	17
Time from symptoms onset to sample collection	< 15 days	3	10
	15-30 days	8	28
	31-45 days	4	14
	> 45	9	48
Hospitalization	Yes	ICU	15
			55
No			14
			45
Fever		16	55
Rhinorrhea		1	3
Anosmia		4	14
Ageusia		3	10
Odynophagia		2	7
Dry cough		11	38
Productive cough		3	10
Dyspnea		11	38
Pneumonia		13	45
Fatigue, myalgia, anorexia		14	48
Pulmonary infiltrate		13	45
Gastrointestinal symptoms		0	0
Cutaneous lesions		0	0
Multiorgan dysfunction		5	17
Thrombotic events		2	7
Comorbidities (HTN, DM, COPD, obesity, cancer)		7	24
Required mechanical ventilation		13	45
Death		2	7

ICU (intensive care unit), HTN (hypertension), DM (diabetes mellitus), COPD (chronic obstructive pulmonary disease).

Supplementary Table 2. Patient demographic for vaccination study

		N=15	%
Gender	Male	5	33.3
	Female	10	66.6
Age (25-56)	25-35	4	26.6
	36-45	4	26.6
	> 46	7	46.6
Days from first dose (2-35)	2 days	1	6.6
	10-20 days	5	33.3
	21-30 days	6	40.0
	> 31	3	20.0
Patients having received 2 nd dose	Y	9	60.0
	N	6	40.0

Supplementary Table 3. Prediction accuracy of healthy vs COVID samples*

Samples		ELISA				FACS Multiantigenic	FACS RBD-Spike-Pro			
Donor	Status	RBD	Spike	NP	Pro	1:100-1:800	1:100	1:200	1:600	1:1800
8	Covid-19	100	100	100	100	100	100	100	100	100
11	Covid-19	100	100	100	100	100	100	100	100	100
14	Covid-19	100	100	100	100	100	100	100	100	100
15	Covid-19	100	100	100	100	100	100	100	100	100
16	Covid-19	100	100	100	100	100	100	100	100	100
18	Covid-19	100	100	100	100	100	100	100	100	100
21	Covid-19	100	100	100	100	100	100	100	100	100
97	Covid-19	100	100	100	100	100	100	100	100	100
102	Covid-19	100	100	100	100	100	100	100	100	100
103	Covid-19	100	100	100	100	100	100	100	100	100
106	Covid-19	100	100	100	100	100	100	100	100	100
107	Covid-19	100	100	100	100	100	100	100	100	100
109	Covid-19	100	100	100	100	100	100	100	100	100
110	Covid-19	100	100	100	100	100	100	100	100	100
128	Covid-19	100	100	11,54	89,87	100	100	100	100	100
35	Covid-19	100	100	100	100	100	100	100	100	100
57	Covid-19	47,43	99,29	0	13,02	99,93	98,46	100	99,78	99,92
92	Covid-19	100	100	100	100	100	100	100	100	100
64	Covid-19	100	99,92	11,72	24,81	100	100	100	99,7	100
99	Covid-19	100	100	100	100	100	100	100	100	100
100	Covid-19	100	100	100	100	100	100	100	100	100
101	Covid-19	100	100	100	100	100	100	100	100	100
129	Covid-19	100	100	100	100	100	100	100	100	100
114	Covid-19	99,37	98,68	100	100	98,24	97,53	99,57	68,26	99,49
89	Covid-19	96,46	100	100	100	100	100	100	100	100
115	Covid-19	100	100	100	100	100	100	100	100	100
121	Covid-19	100	100	100	100	100	100	100	100	100
123	Covid-19	100	100	100	100	100	100	100	100	100
130	Covid-19	100	100	100	100	100	100	100	100	100
43	Control	100	100	100	100	100	100	100	100	100
36	Control	100	100	100	100	100	100	100	100	100
187	Control	100	100	100	100	100	100	100	100	100
94	Control	100	100	100	100	100	100	100	100	100
24	Control	100	100	100	100	100	100	100	100	100
32	Control	100	100	100	100	100	100	100	100	100
33	Control	100	100	100	100	100	100	100	100	100
75	Control	100	100	100	100	100	100	100	100	100
2	Control	100	100	100	100	100	100	100	100	100
8	Control	100	100	100	100	100	100	100	100	100
109	Control	100	100	100	100	100	100	100	100	100
125	Control	100	100	2,29	1,11	100	100	100	100	100
112	Control	100	100	100	100	100	100	100	100	100
80	Control	100	100	100	100	100	100	100	100	100
29	Control	100	100	100	100	100	100	100	100	100

*Samples were stratified and randomly spliced into training and test sets. The training samples were used to fit a random forest classifier which then predicted the healthy vs disease category of unseen test samples (1/7 of total samples). This was repeated n=10,000 times. For each patient, accuracy was calculated as the proportion of correct predictions divided by the number of predictions made